Non-Small Cell Lung Cancer Therapy
Researchers from Osaka City General Hospital, Department of Clinical Oncology report details of new studies and findings in the area of non-small cell lung cancer therapy
Published in Cancer Weekly, May 12th, 2009
A new study, 'Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104),' is now available. According to recent research from Osaka, Japan, "This trial evaluated whether a combination of docetaxel and gemcitabine provides better survival than docetaxel alone in patients with previously treated non-small-cell lung cancer (NSCLC). Eligibility included pathologically or cytologically proven NSCLC, failure of one platinum-based regimen, performance status of zero or one, 20-75 years old, and adequate organ function."
"Patients received docetaxel 60...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2009-05-12)
More Articles from Cancer Weekly
- American Institute of Physics
Simulated gene therapy - Advaxis, Inc.
Advaxis Applies for Approximately $1.0 Million Worth of Grants from the National Institute of Health - Angiogenesis
Researchers from Musashino University report on findings in angiogenesis - Antiretrovirals
New antiretrovirals findings from New York University published - Ardea Biosciences, Inc.
Ardea Biosciences and Bayer HealthCare Enter into Global Agreement Focused on the Development of MEK Inhibitors for the Treatment of Cancer - Array BioPharma Inc.
Array BioPharma’s ARRY-520 Demonstrates Significant Activity in Hematological and Taxane-Resistant Tumors - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
